Furthermore, accumulating evidence suggests that multiple components of EGFRm tumor biology may predict response to ICI therapy, including specific EGFR mutation, TMB, PD-L1 expression, and TIL density among others (Figure 1). Here, CD274 is linked to neoplasm.